How Updated Clinical Standards Put Shared Decision-Making at the Center of Menopause Care

In October 2026, the American College of Obstetricians and Gynecologists (ACOG) updated its menopause-symptom advice for the first time in 12 years, according to Associated Press. The recommendations address disruptive symptoms through hormonal and nonhormonal treatment options.

The update builds on a complicated treatment history

AP places the recommendations against historical concerns about a 2002 study of a particular pill-based estrogen-progestin combination. The report also notes that later studies found benefits outweigh risks for many women. That history does not establish a single risk profile for every current formulation.

The updated advice is not presented as a wholesale reversal of medical consensus. Harvard Medical School professor Dr. JoAnn Manson described it to AP as consistent with guidance from other medical organizations. The central direction is individualized care: treatment decisions should reflect bothersome symptoms and a patient’s circumstances rather than a blanket position for or against hormones.

That distinction matters when reading the headline. A long interval between updates does not mean that every recommendation is a new finding or that every previous treatment decision was mistaken.

The recommendations separate several treatment decisions

• Shared decisions come before choosing a product. ACOG’s reported guidance asks clinicians and patients to weigh hormone therapy’s potential benefits and risks together. Age and medical history belong in that assessment. The starting point is the symptom affecting daily life and the person experiencing it, not an assumption that menopause requires a particular prescription.

For readers preparing for a symptom-led treatment discussion, this gives the conversation a useful focus. Which symptoms are most disruptive? What matters most about relief? Preferences about hormonal or nonhormonal care are part of the discussion rather than something to mention after a treatment has already been selected.

• The age-and-timing advice is conditional. If hormone therapy is appropriate, AP reports that ACOG advises starting before age 60 or within 10 years of menopause. The qualifying phrase belongs with the timing information. This is a consideration within a clinician-patient assessment, not an automatic eligibility rule.

The useful reading is therefore not “under 60 means hormones.” It is that age and time since menopause help inform a decision alongside medical history and the symptoms being treated. A birthday or a calendar calculation cannot replace that assessment. The reported recommendation gives a clinical conversation context rather than supplying a personal treatment answer.

• Whole-body hormone therapy and local vaginal estrogen serve different treatment conversations. AP describes whole-body therapy as available through pills and patches. Other forms include sprays, gels and a vaginal ring. It separately describes low-dose vaginal estrogen as a local treatment often prescribed when vaginal dryness is the main concern.

Those distinctions make the phrase “taking hormones” too broad to explain a treatment plan on its own. A discussion about hot flashes is not necessarily the same discussion as one about vaginal dryness. The report also makes clear why the word “vaginal” alone does not identify whether a treatment is local or whole-body.

For women thinking about comfort and sexual wellbeing, naming the main concern can make the consultation more specific. A clinician can explain which treatment category is being discussed and why it fits that concern.

• Nonhormonal medication is part of the reported options. AP’s account of treatment choices names fezolinetant and elinzanetant, together with certain antidepressants. These are described as alternatives for people who do not want whole-body hormone therapy or are advised against it. AP says fezolinetant and elinzanetant act in a brain region involved in body-temperature regulation.

This gives the conversation somewhere to go when systemic hormones are not the preferred or appropriate route. It does not require treating every nonhormonal medication as interchangeable. The useful next question is which listed option relates to the symptoms under discussion, with selection left to qualified care rather than a general treatment list.

• Non-drug approaches also have a place. The options named in AP’s account include cognitive behavioral therapy and mindfulness. The report also lists exercise, clinical hypnosis and acupuncture. It says these approaches may be used alone or alongside medication for hot flashes, night sweats, sleep or mood problems.

That is a broader treatment conversation than a simple choice between taking hormones and doing nothing. It also leaves room to discuss more than one approach rather than assuming care must stay within a single category. A preference for non-drug care can be stated directly during a consultation.

The practical point is to connect an approach to a particular goal. Relief from disruptive night sweats and support for mood are not identical outcomes. A clear discussion names what the proposed approach is intended to help rather than treating “menopause support” as one undifferentiated promise.

The report summarizes options without providing a full evidence grading

• The treatment list needs to be read within the report’s scope. AP’s coverage does not provide the formal guideline title or the complete underlying recommendation text. It also does not supply evidence-grading details for each intervention. The list should therefore not be read as proof that every option works equally well for every symptom or has the same strength of supporting evidence.

For a personal decision, the useful question is what evidence supports the proposed option for the specific problem being treated. That moves the conversation beyond whether an intervention appears in a news story. It also separates an overview of available choices from the more detailed assessment needed to select care.

The consultation can stay focused on daily life

• Population estimates provide context without explaining an individual’s symptoms. AP reports ACOG estimates that more than half of women in menopause experience hot flashes or night sweats. As many as two-thirds report menopause-related sleep disruption. These figures help explain why the guidance gives those symptoms attention.

They do not establish that a particular woman’s sleep or other changes are caused by menopause. Recognition and assessment are different tasks. The figures can make a concern feel less isolated while leaving room for a clinician to examine the individual experience rather than assigning it a cause from a population estimate.

• The most useful discussion starts with what is disruptive. The practical implication of the coverage is that hot flashes, night sweats or sleep disruption affecting daily life are worth raising with a clinician. ACOG president Dr. Camille Clare urged patients to bring menopause questions to their OB-GYNs and advocate for treatment that meets their needs.

The discussion can cover the symptoms causing the most difficulty and relevant medical history. It can also address treatment preferences and the difference between local care for vaginal dryness and whole-body therapy. Refemina’s coverage of the wider range of menopause concerns offers related context for keeping the conversation broader than hot flashes alone.

• Symptom treatment should not become a general wellness claim. The report concerns options for bothersome menopause symptoms. It does not establish hormone therapy as a weight-loss treatment or an anti-aging intervention. Nor does it support treating hormones as a general-purpose answer to midlife health.

Keeping that boundary clear makes the update more useful. The relevant question is whether a proposed treatment addresses an identified concern with an acceptable balance of benefits and risks. That is more precise than asking whether a treatment is simply good or bad for women at this stage of life.

Future care should start with a more specific conversation

In practice, this update should move menopause consultations toward symptom-specific shared decisions rather than a single treatment default.

How Refemina helps

Keeping menopause treatment in proportion is the next step; Refemina places hormonal change alongside the wider realities of women’s midlife health. For women facing advice that treats symptoms as a reason to sell hormones or supplements, its research-led coverage offers context beyond a product choice or weight-loss goal.

Explore Resources

Sources

1. There's new guidance on menopause symptoms like hot flashes. What women need to know
2. There's new guidance on menopause symptoms like hot flashes. What women need to know